Drugs for Bare Lymphocyte Syndrome, Type Ii (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):
(show top 50)
(show all 92)
# |
|
Name |
Status |
Phase |
Clinical Trials |
Cas Number |
PubChem Id |
1 |
|
Adenosine |
Approved, Investigational |
Phase 4 |
|
58-61-7 |
60961 |
Synonyms:
(2R,3R,4S,5R)-2-(6-amino-9H-purin-9-yl)-5-(hydroxymethyl)oxolane-3,4-diol
(2R,3R,4S,5R)-2-(6-aminopurin-9-yl)-5-(hydroxymethyl)oxolane-3,4-diol
(2R,3R,4S,5R)-2-(6-Aminopurin-9-yl)-5-(hydroxymethyl)oxolane-3,4-diol
1-(6-amino-9H-Purin-9-yl)-1-deoxy-beta-delta-ribofuranose
1-(6-amino-9H-Purin-9-yl)-1-deoxy-beta-D-ribofuranose
1odi
2fqy
2gl0
30143-02-3
46946-45-6
46969-16-8
4-Aminopyrazolo[3,4-d]pyrimidine ribonucleoside
58-61-7
6-Amino-9-.beta.-ribofuranosyl-9H-purine
6-amino-9-b-D-Ribofuranosyl-9H-purine
6-amino-9beta-delta-Ribofuranosyl-9H-purine
6-amino-9beta-D-Ribofuranosyl-9H-purine
6-amino-9-beta-D-Ribofuranosyl-9H-purine
6-Amino-9beta-D-ribofuranosyl-9H-purine
6-Amino-9-beta-D-ribofuranosyl-9H-purine
6-amino-9-β-D-ribofuranosyl-9H-purine
9-(beta-D-Arabinofuranosyl)adenine
9-b-D-Ribofuranosidoadenine
9-b-D-Ribofuranosyl-9H-purin-6-amine
9-beta-D-Arabinofuranosyladenine
9-beta-delta-Arabinofuranosyladenine
9-beta-delta-Ribofuranosidoadenine
9beta-delta-Ribofuranosyl-9H-purin-6-amine
9-beta-delta-Ribofuranosyl-9H-purin-6-amine
9beta-delta-Ribofuranosyladenine
9-beta-delta-Ribofuranosyladenine
9-beta-D-Ribofuranosidoadenine
9beta-D-Ribofuranosyl-9H-purin-6-amine
9-beta-D-Ribofuranosyl-9H-purin-6-amine
9beta-D-Ribofuranosyladenine
9-beta-D-Ribofuranosyladenine
9-β-D-ribofuranosidoadenine
9-β-D-ribofuranosyl-9H-purin-6-amine
A0152
A4036_SIGMA
A9251_SIGMA
AC1L1U8O
AC1Q1ID3
AC1Q52XU
Adenin riboside
Adenine 9-beta-D-arabinofuranoside
Adenine deoxyribonucleoside
Adenine Deoxyribonucleoside
Adenine nucleoside
Adenine riboside
Adenine-9beta-delta-ribofuranoside
Adenine-9beta-D-ribofuranoside
Adenine-9-beta-D-ribofuranoside
adenine-D-ribose
Adenocard
Adenocard (TN)
Adenocard, Adenosine
Adenocor
Adenogesic
Adenoscan
Adenoscan (TN)
Adenosin
Adenosin [German]
Adenosina
adenosine
Adenosine
Adénosine
Adenosine (JAN/USP)
Adenosine [USAN:BAN]
Adenosine, homopolymer
Adenosinum
Adensoine
Adenyldeoxyriboside
Ade-rib
Ade-Rib
|
ADN
Ado
AI3-52413
BB_NC-0565
b-D-Adenosine
beta-Adenosine
beta-D-Adenosine
beta-delta-Adenosine
beta-D-Ribofuranoside, adenine-9
Bio1_000437
Bio1_000926
Bio1_001415
bmse000061
Boniton
BSPBio_001796
C00212
Caswell No. 010B
CCRIS 2557
CHEBI:16335
CHEMBL477
CID60961
D000241
D00045
DB00640
Deoxyadenosine
Desoxyadenosine
EA6C60C2-6AFB-4264-A2F0-541373DB950E
EINECS 200-389-9
FT-0082881
HMS1920A13
HMS2091G13
KBio3_001296
LS-15085
MEDR-640
MLS000069638
MLS002153227
MolPort-001-838-229
Myocol
NCGC00023673-03
NCGC00023673-04
NCGC00023673-05
NCGC00023673-06
NCGC00023673-07
nchembio.143-comp9
nchembio.186-comp109
nchembio.2007.56-comp13
nchembio.64-comp4
nchembio706-5
NSC 627048
NSC 7652
NSC627048
NSC7652
Nucleocardyl
Pallacor
Polyadenosine
Polyriboadenosine
S1647_Selleck
Sandesin
SDCCGMLS-0003108.P003
SMR000058216
SPBio_001194
SPECTRUM1500107
Spectrum2_001257
Spectrum3_000288
SR 96225
SR-96225
SUN-Y4001
TL8003749
UNII-K72T3FS567
USAF CB-10
V0098
Vidarabine
ZINC02169830
β-D-adenosine
|
|
2 |
|
Rho(D) Immune Globulin |
|
Phase 3 |
|
|
|
3 |
|
Immunoglobulins, Intravenous |
|
Phase 3 |
|
|
|
4 |
|
gamma-Globulins |
|
Phase 3 |
|
|
|
5 |
|
Immunoglobulin G |
|
Phase 3 |
|
|
|
6 |
|
Methotrexate |
Approved |
Phase 2 |
|
59-05-2, 1959-05-2 |
126941 |
Synonyms:
4-amino-10-Methylfolate
4-amino-10-methylfolic acid
4-amino-10-Methylfolic acid
4-amino-N(10)-Methylpteroylglutamate
4-amino-N(10)-methylpteroylglutamic acid
4-amino-N(10)-Methylpteroylglutamic acid
Abitrexate
Amethopterin
Amethopterine
Antifolan
Arbitrexate
Dicesium salt methotrexate
Emtexate
Emtexic acid
Folex
HDMTX
Hydrate, methotrexate
L-Amethopterin
Ledertrexate
Ledertrexic acid
Metatrexan
Methopterin
Methotextrate
Methotrate
Methotrexat
|
Methotrexate
Méthotrexate
Methotrexate hydrate
Methotrexate sodium
Methotrexate Sodium
Methotrexate, (D)-isomer
Methotrexate, (DL)-isomer
Methotrexate, dicesium salt
Methotrexate, disodium salt
Methotrexate, sodium salt
Methotrexatum
Methotrexic acid
Methylaminopterin
Methylaminopterinum
Metotrexato
Mexate
MTX
N-[4-[[(2,4-diamino-6-Pteridinyl)methyl]methylamino]benzoyl]-L-glutamate
N-[4-[[(2,4-diamino-6-pteridinyl)methyl]methylamino]benzoyl]-L-glutamic acid
N-[4-[[(2,4-diamino-6-Pteridinyl)methyl]methylamino]benzoyl]-L-glutamic acid
N-Bismethylpteroylglutamic acid
N-Bismethylpteroylglutamic Acid
Rheumatrex
Sodium, methotrexate
Trexall
|
|
7 |
|
leucovorin |
Approved |
Phase 2 |
|
58-05-9 |
6006 143 |
Synonyms:
(5-formyl-5,6,7,8-tetrahydropteroyl)glutamate
(6R,S)-5-Formyltetrahydrofolate
10-Formyl-7,8-dihydrofolate
10-Formyl-7,8-dihydrofolic acid
5 Formyltetrahydrofolate
5 Formyltetrahydropteroylglutamate
5-Formyl-5,6,7,8-tetrahydrofolate
5-Formyl-5,6,7,8-tetrahydrofolic acid
5-Formyl-5,6,7,8-tetrahydropteroyl-L-glutamic acid
5-formyltetrahydrofolate
5-Formyltetrahydrofolate
5-formyltetrahydrofolic acid
5-Formyltetrahydrofolic acid
5-Formyltetrahydropteroylglutamate
5-Formyltetrahydropteroylglutamic acid
5-formylTHF
Acid, folinic
Acide folinique
Acido folinico
Calcium citrovorum factor
Calcium folinate
Calcium leucovorin
Citrovorum factor
Factor, citrovorum
Folinate
Folinate, calcium
Folinic acid
Folinic acid calcium salt
Folinic acid calcium salt USP27
Folinic acid SF
Folinic acid-SF
|
L(-)-5-Formyl-5,6,7,8-tetrahydrofolate
L(-)-5-Formyl-5,6,7,8-tetrahydrofolic acid
Leucal
Leucovorin
Leucovorin calcium
Leucovorin folinic acid
Leucovorin, (D)-isomer
Leucovorin, (DL)-isomer
Leucovorin, (R)-isomer
Leucovorin, calcium
Leucovorin, calcium (1:1) salt
Leucovorin, calcium (1:1) salt, (DL)-isomer
Leucovorin, calcium (1:1) salt, pentahydrate
Leucovorin, monosodium salt
Leucovorinum
Leukovorin
Leukovorum
Levoleucovorin
L-leucovorin
L-Leucovorin
L-N-[P-[[(2-amino-5-Formyl-5,6,7,8-tetrahydro-4-hydroxy-6-pteridinyl)methyl]amino]benzoyl]-glutamic acid
Monosodium salt leucovorin
N(5)-Formyltetrahydrofolate
N-(5-formyl-5,6,7,8-tetrahydropteroyl)-L-glutamic acid
N5-Formyl-5,6,7,8-tetrahydrofolate
N5-Formyl-5,6,7,8-tetrahydrofolic acid
N5-Formyltetrahydrofolate
N5-Formyltetrahydrofolic acid
Rescuvolin
Welcovorin
Wellcovorin
|
|
8 |
|
Levoleucovorin |
Approved, Investigational |
Phase 2 |
|
68538-85-2 |
|
Synonyms:
(6S)-5-Formyl-5,6,7,8-tetrahydrofolic acid
(6S)-5-formyltetrahydrofolic acid
(6S)-Folinic acid
(6S)-Leucovorin
(S)-Leucovorin
ácido levofolínico
|
Citrovorum factor
Levofolene
Levofolinic acid
L-Folinic acid
N-[4-({[(6S)-2-amino-5-formyl-4-oxo-1,4,5,6,7,8-hexahydropteridin-6-yl]methyl}amino)benzoyl]-L-glutamic acid
|
|
9 |
|
Tacrolimus |
Approved, Investigational |
Phase 2 |
|
104987-11-3 |
445643 439492 6473866 |
Synonyms:
(-)-FK 506
(3S,4R,5S,8R,9E,12S,14S,15R,16S,18R,19R,26aS)-5,19-dihydroxy-3-{(1E)-1-[(1R,3R,4R)-4-hydroxy-3-methoxycyclohexyl]prop-1-en-2-yl}-14,16-dimethoxy-4,10,12,18-tetramethyl-8-(prop-2-en-1-yl)-5,6,8,11,12,13,14,15,16,17,18,19,24,25,26,26a-hexadecahydro-3H-15,19-epoxypyrido[2,1-c][1,4]oxazacyclotricosine-1,7,20,21(4H,23H)-tetrone
104987-11-3
109581-93-3 (Hydrate)
15,19-epoxy-3H-pyrido[2,1-c][1,4]oxaazacyclotricosine-1,7,20,21(23H)-tetrone,
3S-[3R*[E(1S*,3S*,4S*)],4S*,5R*,8S*,9E,12R*,14R*,15S*,16R*,18S*,19S*,26aR*]]-5,6,8,11,12,13,14,15,16,17,18,19,24,25,26,26a-hexadecahydro-5, 19-dihydroxy-3-[2-(4-hydroxy-3-methoxycyclohexyl)-1-methylethenyl]-14,16-dimethoxy-4,10,12,18-tetramethyl-8-(2-propenyl)-15,19-epoxy-3H-pyrido[2,1-c] [1,4] oxaazacyclotricosine-1,7,20,21(4H,23H)-tetrone
8-DEETHYL-8-[BUT-3-ENYL]-ASCOMYCIN
AC-1182
AC1L1K7H
AC1L97GB
AC1L9IBU
Advagraf
AKOS005145901
Ambap104987-11-3
Ambap5429
Anhydrous tacrolimus
Anhydrous, tacrolimus
BCBcMAP01_000194
Bio-0921
Bio2_000470
Bio2_000950
BRD-K35452788-001-02-1
BSPBio_001279
BSPBio-001279
C01375
C44H69NO10
CCRIS 7124
CHEBI:100924
CHEBI:61049
CHEMBL1200738
CID11158639
CID11556866
CID439492
CID445643
CID5372
CID5472317
CID6426916
CID6436007
CID6473866
CID6536850
CID6610362
CID6912836
CID9832283
CID9853905
CID9918805
CID9940643
CID9963169
Cilag brand OF tacrolimus
CPD000466356
CPD-10016
D08556
DB00864
DivK1c_001040
FK 506
FK5
Fk-506
FK506
FK-506
FR 900506
FR900506
|
FR-900506
FT-0082660
Fujimycin
Fujisawa brand OF tacrolimus
Graceptor
HMS1362O21
HMS1792O21
HMS1990O21
HMS2051C18
HMS2093M19
HMS503O21
IDI1_001040
IDI1_002225
Janssen brand OF tacrolimus
K506
KBio1_001040
KBio2_000619
KBio2_003187
KBio2_005755
KBio3_001097
KBio3_001098
KBioGR_000619
KBioSS_000619
L 679934
L-679934
LCP-Tacro
LMPK04000003
LS-64247
MLS000759471
MLS001424054
Modigraf
MolPort-003-666-518
NCGC00163470-01
NCGC00163470-02
NCGC00163470-03
NCGC00163470-04
NCGC00179232-01
NChemBio.2007.16-comp1
nchembio.2007.23-comp2
NINDS_001040
NSC717865
Prograf
Prograf (TN)
Prograft
Protopic
Protopy
S5003_Selleck
SAM001246677
SMR000466356
Tacarolimus
tacrolimus
Tacrolimus
Tacrolimus (anhydrous)
Tacrolimus (INN)
Tacrolimus (Prograf?)
Tacrolimus anhydrous
tacrolimus hydrate
Tacrolimus, anhydrous
Tsukubaenolide
UNII-Y5L2157C4J
|
|
10 |
|
Mechlorethamine |
Approved, Investigational |
Phase 2 |
|
51-75-2 |
4033 |
Synonyms:
.Beta.,.beta.'-Dichlorodiethyl-N-methylamine
1, 5-Dichloro-3-methyl-3-azapentane hydrochloride
126-85-2 (N-oxide)
2,2'-Dichlorodiethyl-methylamine
2,2'-Dichloro-N-me
2,2'-dichloro-N-methyldiethylamine
2,2'-dichloro-N-Methyldiethylamine
2,2'-Dichloro-N-methyldiethylamine
2-Chloro-N-(2-chloroethyl)-N-methylethanamine
302-70-5 (N-oxide, hydrochloride)
51-75-2
55-86-7 (HYDROCHLORIDE)
AC1L1H9H
Antimit
b,Beta'-dichlorodiethyl-N-methylamine
beta,beta'-Dichlorodiethyl-N-methylamine
beta,Beta'-dichlorodiethyl-N-methylamine
bis(2-chloroethyl)methylamine
Bis(2-chloroethyl)methylamine
Bis(b-chloroethyl)methylamine
Bis(beta-chloroethyl) methylamine
Bis(beta-chloroethyl)methylamine
bis(β-chloroethyl)methylamine
Bis(β-chloroethyl)methylamine
BRN 0605323
BSPBio_001947
C07115
C5H11Cl2N
Carolysine
Caryolysin
Caryolysine
CCRIS 447
CHEBI:28925
CHEMBL427
Chloramine (the nitrogen mustard)
Chlorethazine
Chlormethine
Chlormethine (INN)
Chlormethine [INN:BAN]
Chlormethinum
Chlormethinum [INN-Latin]
CID4033
Cloramin
Clormetina
Clormetina [INN-Spanish]
D07671
DB00888
Di(2-chloroethyl)methylamine
Dichlor amine
Dichloren
DivK1c_000759
EINECS 200-120-5
Embechine
Embichin
ENT-25294
HMS1920J15
HMS2091B04
HMS502F21
HN2
HN-2
HSDB 5083
Hydrochloride N-oxide, mechlorethamine
Hydrochloride, mechlorethamine
I14-8708
IBS-L0033631
IDI1_000759
KBio1_000759
KBio2_001369
KBio2_003937
KBio2_006505
KBio3_001447
KBioGR_001448
KBioSS_001369
LS-7559
MBA
Me chloroethamine
Mebichloramine
mechlorethamine
|
Mechlorethamine
Mechlorethamine hydrochloride
Mechlorethamine hydrochloride N oxide
Mechlorethamine hydrochloride N-oxide
Mechlorethamine N oxide
Mechlorethamine N-oxide
Mechlorethamine oxide
Mechlorethanamine
Mechloroethamine
Mecloretamina
Mecloretamina [Italian]
Merck brand OF mechlorethamine hydrochloride
Merck frosst brand OF mechlorethamine hydrochloride
methylbis(2-chloroethyl)amine
Methylbis(2-chloroethyl)amine
Methylbis(b-chloroethyl)amine
Methylbis(beta-chloroethyl)amine
methylbis(β-chloroethyl)amine
Methylbis(β-chloroethyl)amine
Methylchlorethamine
Methyldi(2-chloroethyl)amine
Mitomen
Mitoxine (*Hydrochloride*)
MolPort-001-785-592
Mustargen
Mustine
Mustine note
Mutagen
N,N-Bis(2-chloroethyl)methylamine
N,N-Bis(2-chloroethyl)-N-methylamine
N,N-Di(chloroethyl)methylamine
NCGC00091835-02
NCGC00091835-03
NCGC00091835-04
NCGC00091835-05
NCI60_041682
NINDS_000759
Nitol (*Hydrochloride*)
Nitrogen mustard
Nitrogen mustard (HN-2)
Nitrogen mustard N oxide
Nitrogen mustard N-oxide
Nitrogranulogen
Nitromin
N-Lost
N-Methyl lost
N-Methyl-2,2'-dichlorodiethylamine
N-methyl-bis(2-chloroethyl)amine
N-Methyl-bis(2-chloroethyl)amine
N-Methyl-bis(b-chloroethyl)amine
N-Methyl-bis(beta-chloroethyl)amine
N-methyl-bis(β-chloroethyl)amine
N-Methyl-bis(β-chloroethyl)amine
N-Methyl-bis-chloraethylamin
N-Methyl-bis-chloraethylamin [German]
N-Methyl-lost
N-Methyl-lost [German]
N-Oxide, mechlorethamine hydrochloride
N-Oxide, nitrogen mustard
NSC 762
NSC762
NSC-762
SPBio_000496
Spectrum_000889
SPECTRUM1500375
Spectrum2_000448
Spectrum3_000484
Spectrum4_000924
Spectrum5_001702
Stickstofflost (*Hydrochloride*)
Stickstofflost (ebewe)
T 1024
T-1024
thyldiethylamine
TL 146
UNII-50D9XSG0VR
β,beta'-dichlorodiethyl-N-methylamine
β,β'-dichlorodiethyl-N-methylamine
|
|
11 |
|
Hydroxyurea |
Approved |
Phase 2 |
|
127-07-1 |
3657 |
Synonyms:
127-07-1
1-HYDROXYUREA
4-03-00-00170 (Beilstein Handbook Reference)
55291_FLUKA
AC1L1GF8
AC1Q4ZXK
AI3-51139
BB_SC-7256
Bio1_000451
Bio1_000940
Bio1_001429
Biosupressin
BRN 1741548
BSPBio_002164
C07044
carbamide oxide
Carbamohydroxamate
Carbamohydroxamic acid
Carbamohydroxamic Acid
Carbamohydroximate
Carbamohydroximic acid
Carbamohydroximic Acid
Carbamohydroxyamic acid
Carbamohydroxyamic Acid
Carbamoyl oxime
Carbamoyl Oxime
Carbamyl hydroxamate
Carbamyl Hydroxamate
Carbamyl hydroxamic acid
Carrbamoyl Oxime
CCRIS 958
CHEBI:44423
CHEMBL467
CID3657
D00341
D006918
DB01005
DivK1c_000556
DRG-0253
Droxia
Droxia (TM)
Droxia (TN)
E0723DBA-5AF3-49D1-B5F6-59420AB87AC9
EINECS 204-821-7
EU-0100596
FT-0083575
H 8627
H0310
H20210
H8627_SIGMA
Hidrix
Hidroxicarbamida
Hidroxicarbamida [INN-Spanish]
HMS1920F09
HMS2091L17
HMS501L18
HSDB 6887
HU
Hydrea
Hydrea (TM)
HYDREA (TN)
Hydrea, Biosupressin, Cytodrox, Hydroxyurea
Hydreia
Hydroxicarbamidum
hydroxyaminomethanamide
Hydroxycarbamid
Hydroxycarbamide
Hydroxycarbamide (JAN/INN)
Hydroxycarbamidum
Hydroxycarbamidum [INN-Latin]
Hydroxycarbamine
Hydroxyharnstoff
Hydroxyharnstoff [German]
Hydroxylurea
hydroxyurea
Hydroxyurea
HYDROXY-UREA
Hydroxyurea (D4)
|
Hydroxyurea (USP)
Hydroxyurea [USAN:BAN]
Hydroxyurea(d4)
Hydura
Hydurea
I05-0250
IDI1_000556
Idrossicarbamide
Idrossicarbamide [Dcit]
Idrossicarbamide [DCIT]
KBio1_000556
KBio2_001389
KBio2_003957
KBio2_006525
KBio3_001384
KBioGR_000383
KBioSS_001389
Litaler
Litalir
Lopac0_000596
Lopac-H-8627
LS-709
MLS001332381
MLS001332382
MLS002153389
MolMap_000029
MolPort-000-003-971
Mylocel
N-(Aminocarbonyl) Hydroxyamine
N-Carbamoylhydroxylamine
NCGC00015520-01
NCGC00015520-02
NCGC00015520-07
NCGC00093974-01
NCGC00093974-02
NCGC00093974-03
NCGC00093974-04
NCGC00093974-05
nchembio.573-comp3
nchembio.90-comp4
nchembio749-comp3
NCI C04831
NCI60_002773
NCI-C04831
NCIMech_000139
NHY
N-HYDROXY UREA
N-Hydroxymocovina
N-Hydroxymocovina [Czech]
N-Hydroxyurea
N-HYDROXYUREA
NINDS_000556
NSC 32065
NSC32065
Oncocarbide
Onco-carbide
Onco-Carbide
Oxyurea
S1896_Selleck
Siklos
SK 22591
SMR000059149
SPBio_000247
Spectrum_000909
SPECTRUM1500344
Spectrum2_000064
Spectrum3_000462
Spectrum4_000012
Spectrum5_000836
S-phase/G-1 interface inhibitor
SQ 1089
SQ-1089
Sterile Urea
tetratogen: inhibits ribonucleoside diphosphate reductase
TL8000673
UNII-X6Q56QN5QC
Ureaphil
WLN: ZVMQ
|
|
12 |
|
Thiotepa |
Approved, Investigational |
Phase 2 |
|
52-24-4 |
5453 |
Synonyms:
Girostan
Tepadina
Tespa
Tespamin
thio Tepa
Thiophosphamide
|
Thioplex
thio-Tepa
Thiotepa
Triethylenethiophosphoramide
Tris(1-aziridinyl)phosphine sulfide
|
|
13 |
|
Ezetimibe |
Approved |
Phase 2 |
|
163222-33-1 |
150311 |
Synonyms:
(-)-Sch 58235
(1-(4-fluorophenyl)-(3R)-(3-(4-fluorophenyl)-(3S)-hydroxypropyl)-(4S)-(4-hydroxyphenyl)-2-azetidinone)
(1-(4-Fluorophenyl)-(3R)-(3-(4-fluorophenyl)-(3S)-hydroxypropyl)-(4S)-(4-hydroxyphenyl)-2-azetidinone)
(3R,4S)-1-(4-fluorophenyl)-3-[(3S)-3-(4-fluorophenyl)-3-hydroxypropyl]-4-(4-hydroxyphenyl)azetidin-2-one
(3R,4S)-1-(p-Fluorophenyl)-3-((3S)-3-(p-fluorophenyl)-3-hydroxypropyl)-4-(p-hydroxyphenyl)-2-azetidinone
1-(4-fluorophenyl)-3(R)-[3-(4-fluorophenyl)-3(S)-(4-hydroxyphenyl)-2-azetidione
1-(4-fluorophenyl)-3(R)-[3-(4-fluorophenyl)-3(S)-hydroxypropyl]-4(S)-(4-hydroxyphenyl)-2-azetidinone
163222-33-1
AC-1057
AC1L442L
C108606
CHEBI:49040
CHEMBL1138
CID150311
CPD000466334
D01966
DB00973
Essex brand of ezetimibe
Ezedoc
ezetimib
Ezetimib
Ezetimiba
Ezetimibe
ézétimibe
Ezetimibe (JAN/USAN/INN)
Ezetimibe [USAN:INN]
|
Ezetimibum
Ezetrol
HMS2051K16
LS-181801
Merck brand of ezetimibe
MK-0653
MLS000759443
MLS001424125
MolPort-005-938-627
MSD brand of ezetimibe
S1655_Selleck
SAM001246623
Sch 58235
SCH58235
SCH-58235
Schering-Plough brand of ezetimibe
SMR000466334
STK640490
STOCK6S-73750
UNII-EOR26LQQ24
Zetia
Zetia (TN)
Zetia , Ezetrol, Ezetimibe
Zient
ZINC03810860
|
|
14 |
|
Fludarabine |
Approved |
Phase 1, Phase 2 |
|
21679-14-1, 75607-67-9 |
30751 |
Synonyms:
(2R,3S,4S,5R)-2-(6-amino-2-fluoro-9H-purin-9-yl)-5-(hydroxymethyl)oxolane-3,4-diol
(2R,3S,4S,5R)-2-(6-amino-2-fluoropurin-9-yl)-5-(hydroxymethyl)oxolane-3,4-diol
21679-14-1
2-F-ara-A
2-F-ARAA
2F-Ara-AMP
2-fluoro ARA-A
2-Fluoro Ara-A
2-Fluoro-9-beta-D-arabinofuranosyladenine
2-Fluoroadenine arabinoside 5'-monophosphate
2-Fluoroadenine arabinoside 5'-monophosphoric acid
2-fluoro-ARA AMP
9 beta-D-Arabinofuranosyl-2-fluoroadenine monophosphate
9-b-Arabinofuranosyl-2-fluoroadenine-5'-phosphate
9-b-Arabinofuranosyl-2-fluoroadenine-5'-phosphoric acid
9-b-D-Arabinofuranosyl-2-fluoroadenine 5'-(dihydrogen phosphate)
9-b-D-Arabinofuranosyl-2-fluoroadenine 5'-(dihydrogen phosphoric acid)
9-b-D-Arabinofuranosyl-2-fluoroadenine 5'-monophosphate
9-b-D-Arabinofuranosyl-2-fluoroadenine 5'-monophosphoric acid
9-beta-Arabinofuranosyl-2-fluoroadenine-5'-phosphate
9-beta-Arabinofuranosyl-2-fluoroadenine-5'-phosphoric acid
9-beta-D-arabinofuranosyl-2-fluoro-9H-purin-6-amine
9-beta-D-Arabinofuranosyl-2-fluoroadenine
9-beta-D-Arabinofuranosyl-2-fluoroadenine 5'-(dihydrogen phosphate)
9-beta-D-Arabinofuranosyl-2-fluoroadenine 5'-(dihydrogen phosphoric acid)
9-beta-D-Arabinofuranosyl-2-fluoroadenine 5'-monophosphate
9-beta-D-Arabinofuranosyl-2-fluoroadenine 5'-monophosphoric acid
9H-Purin-6-amine, 9-beta-D-arabinofuranosyl-2-fluoro- (9CI)
9-β-arabinofuranosyl-2-fluoroadenine-5'-phosphate
9-β-arabinofuranosyl-2-fluoroadenine-5'-phosphoric acid
9-β-D-arabinofuranosyl-2-fluoroadenine 5'-(dihydrogen phosphate)
9-β-D-arabinofuranosyl-2-fluoroadenine 5'-(dihydrogen phosphoric acid)
9-β-D-arabinofuranosyl-2-fluoroadenine 5'-monophosphate
9-β-D-arabinofuranosyl-2-fluoroadenine 5'-monophosphoric acid
AC1LCW8I
AC1Q51CF
Beneflur
C10H12FN5O4
CCRIS 3382
CHEMBL1568
CID657237
|
CPD000058874
D07966
EINECS 244-525-5
FAMP
FaraA
F-Ara-A
FaraAMP
F-Ara-AMP
Fludara
Fludara, Fludarabine
Fludarabina
Fludarabina [Spanish]
Fludarabine
Fludarabine (INN)
Fludarabine [INN]
Fludarabine 5'-monophosphate
Fludarabine 5'-monophosphoric acid
Fludarabine monophosphate
Fludarabine monophosphoric acid
Fludarabine phosphate
Fludarabinum
Fludarabinum [Latin]
Fludura
fluoro-Ara-AMP
Fluradosa
Fluradosa (TN)
FT-0082766
HSDB 6964
I14-4978
LS-15061
MLS000028687
NSC 118218
NSC 118218H
NSC-118218
S1491_Selleck
SAM002548956
SMR000058874
SQ Fludarabine
UNII-1X9VK9O1SC
UNII-P2K93U8740
ZINC04216238
|
|
15 |
|
alemtuzumab |
Approved, Investigational |
Phase 1, Phase 2 |
|
216503-57-0 |
|
Synonyms:
|
16 |
|
Lenograstim |
Approved, Investigational |
Phase 2 |
|
135968-09-1 |
|
Synonyms:
G-CSF (CHO cell derived)
Glycosylated recombinant G-CSF
Glycosylated recombinant granulocyte colony stimulating factor
Granulocyte colony stimulating factor 3 (CHO cell derived)
|
Granulocyte colony-stimulating factor lenograstim
Lenograstim
Lenograstim (genetical recombination)
Lenograstim rDNA
|
|
17 |
|
Busulfan |
Approved, Investigational |
Phase 2 |
|
55-98-1 |
2478 |
Synonyms:
1, {4-Bis[methanesulfonoxy]butane}
1, 4-Dimethanesulfonoxybutane
1, 4-Dimethylsulfonoxybutane
1,4-Bis(methanesulfonoxy)butane
1,4-Bis(methanesulfonyloxy)butane
1,4-Bis(methanesulphonoxy)butane
1,4-Bis[methanesulfonoxy]butane
1,4-Butanedi yl dimethanesulfonate
1,4-Butanediol dimethanesulfonate
1,4-BUTANEDIOL DIMETHANESULFONATE
1,4-Butanediol dimethanesulfonic acid
1,4-Butanediol dimethanesulphonate
1,4-Butanediol dimethanesulphonic acid
1,4-Butanediol dimethylsulfonate
1,4-Butanediol, dimethanesulfonate
1,4-Butanediol, dimethanesulphonate
1,4-Butanediyl dimethanesulfonate
1,4-Di(methylsulfonoxy)butane
1,4-Dimesyloxybutane
1,4-Dimethane sulfonyl oxybutane
1,4-Dimethanesulfonoxybutane
1,4-Dimethanesulfonoxylbutane
1,4-Dimethanesulfonyloxybutane
1,4-Dimethanesulphonoxybutane
1,4-Dimethanesulphonyloxybutane
1,4-Dimethylsulfonoxybutane
1,4-Dimethylsulfonyloxybutane
2041 C. B
2041 C. B.
2041 C.B
2041 C.B.
4-((Methylsulfonyl)oxy)butyl methanesulfonate
4-methylsulfonyloxybutyl methanesulfonate
55-98-1
AC-198
AC1L1DRQ
AC1Q4GRQ
acid, tetramethylene ester
AI3-25012
AKOS003614975
alkylating agent: crosslinks guanine residues
Ambap55-98-1
AN 33501
B1022
B2635_FLUKA
B2635_SIGMA
Bisulfex
Bisulphex
BRN 1791786
BSPBio_001920
Busilvex
busulfan
Busulfan
BUSULFAN (1,4-BUTANEDIOL, DIMETHANESULFONATE)
Busulfan (JP15/USP/INN)
Busulfan [INN:JAN]
Busulfan glaxosmithkline brand
Busulfan GlaxoSmithKline Brand
Busulfan orphan brand
Busulfan Orphan Brand
Busulfan wellcome
Busulfan Wellcome
Busulfan wellcome brand
Busulfan Wellcome Brand
Busulfano
Busulfano [INN-Spanish]
Busulfanum
Busulfanum [INN-Latin]
Busulfex
Busulphan
Busulphane
Busulphano
Busulphanum
butane-1,4-diyl dimethanesulfonate
Butanedioldimethanesulfonate
Buzulfan
C.B. 2041
C6H14O6S2
CB 2041
CCRIS 418
CHEBI:28901
CHEMBL820
CID2478
Citosulfan
CPD000058613
D002066
D00248
DB01008
DivK1c_000847
EINECS 200-250-2
FT-0083567
G.T. 41
glaxo Wellcome brand OF busulfan
Glaxo Wellcome Brand of Busulfan
GlaxoSmithKline brand OF busulfan
GlaxoSmithKline Brand of Busulfan
Glyzophrol
|
GT 2041
GT 41
HMS1920I07
HMS2091O09
HMS502K09
HSDB 7605
I09-1371
IDI1_000847
InChI=1/C6H14O6S2/c1-13(7,8)11-5-3-4-6-12-14(2,9)10/h3-6H2,1-2H3
KBio1_000847
KBio2_000512
KBio2_003080
KBio2_005648
KBio3_001420
KBioGR_000698
KBioSS_000512
Leucosulfan
Leucosulphan
LS-1358
Mablin
Methanesulfonic
Methanesulfonic acid, tetram ethylene ester
Methanesulfonic acid, tetramethylene ester
Mielevcin
Mielosan
Mielucin
Milecitan
Mileran
Misulban
Mitosan
Mitostan
MLS001076666
MolPort-001-783-406
Myeleukon
Myeloleukon
Myelosan
Myelosanum
Mylecytan
Myleran
Myléran
MYLERAN (TN)
Myleran tablets
Myleran Tablets
Myleran, Busulfex, Busulfan
Mylerlan
n-Butane-1,3-di(methylsulfonate)
N-Butane-1,3-di(methylsulfonate)
NCGC00090905-01
NCGC00090905-02
NCGC00090905-03
NCGC00090905-04
NCGC00090905-05
NCGC00090905-06
NCGC00090905-07
NCI60_041640
NCI-C01592
NCIMech_000192
NINDS_000847
NSC 750
NSC750
NSC-750
NSC-750sulphabutin
Orphan brand OF busulfan
Orphan Brand of Busulfan
Prestwick_989
S1692_Selleck
SAM002554887
SMR000058613
SPBio_000253
Spectrum_000092
SPECTRUM1500152
Spectrum2_000067
Spectrum3_000320
Spectrum4_000259
Spectrum5_000928
ST50825921
Sulfabutin
Sulfabutin (VAN)
Sulphabutin
Tetramethylene {bis[methanesulfonate]}
Tetramethylene bis(methanesulfonate)
Tetramethylene bis(methanesulfonic acid)
Tetramethylene bis(methanesulphonate)
Tetramethylene bis(methanesulphonic acid)
Tetramethylene bis[methanesulfonate]
Tetramethylene dimethane sulfonate
Tetramethylene Dimethane Sulfonate
Tetramethylenester kyseliny methansulfonove
Tetramethylenester Kyseliny Methansulfonove
Tetramethylenester kyseliny methansulfonove [Czech]
UNII-G1LN9045DK
Wellcome brand OF busulfan
Wellcome Brand of Busulfan
Wellcome, busulfan
Wellcome, Busulfan
WLN: WS1&O4OSW1
X 149
|
|
18 |
|
Cyclophosphamide |
Approved, Investigational |
Phase 2 |
|
50-18-0, 6055-19-2 |
2907 |
Synonyms:
(-)-Cyclophosphamide
(+-)-Cyclophosphamide
(RS)-Cyclophosphamide
1-(bis(2-chloroethyl)amino)-1-oxo-2-aza-5-oxaphosphoridine
1-Bis(2-chloroethyl)amino-1-oxo-2-aza-5-oxaphosphoridin
2-[Bis(2-chloroethylamino)]-tetrahydro-2H-1,3,2-oxazaphosphorine-2-oxide
4-Hydroxy-cyclophosphan-mamophosphatide
50-18-0
60007-95-6
6055-19-2 (monohydrate)
75526-90-8
AC1L1EQQ
AI3-26198
Anhydrous cyclophosphamide
Anhydrous, cyclophosphamide
ASTA
Asta B 518
ASTA B518
B 518
B-518
bis(2-Chloroethyl)phosphami de cyclic propanolamide
bis(2-Chloroethyl)phosphamide cyclic propanolamide ester
Bis(2-chloroethyl)phosphoramide cyclic propanolamide ester
BRN 0011744
BSPBio_002099
C 0768
C07888
C7H15Cl2N2O2P
CB 4564
CB-4564
CCRIS 188
CHEBI:4027
CHEMBL32520
CHEMBL88
Ciclofosfamida
Ciclofosfamida [INN-Spanish]
Ciclofosfamide
Ciclophosphamide
Ciclophosphamide [INN]
CID2907
Clafen
Claphene
CP
CPA
CTX
CY
Cycloblastin
Cyclophosphamid
cyclophosphamide
Cyclophosphamide
Cyclophosphamide (anhydrous form)
Cyclophosphamide (anhydrous)
Cyclophosphamide (INN)
Cyclophosphamide (TN)
Cyclophosphamide anhydrous
Cyclophosphamide monohydrate
Cyclophosphamide Monohydrate
Cyclophosphamide Sterile
Cyclophosphamide, (+-)-Isomer
Cyclophosphamide, (R)-isomer
Cyclophosphamide, (S)-isomer
Cyclophosphamides
Cyclophosphamidum
Cyclophosphamidum [INN-Latin]
Cyclophosphan
Cyclophosphane
Cyclophosphanum
Cyclophosphoramide
Cyclostin
Cyklofosfamid
Cyklofosfamid [Czech]
Cytophosphan
Cytophosphane
Cytoxan
|
Cytoxan (TN)
Cytoxan Lyoph
D,L-Cyclophosphamide
D07760
DB00531
DivK1c_000246
EINECS 200-015-4
Endoxan
Endoxan R
Endoxana
Endoxanal
Endoxan-Asta
Endoxane
Enduxan
EU-0100238
Genoxal
Hexadrin
HMS2090A12
HSDB 3047
IDI1_000246
KBio1_000246
KBio2_001338
KBio2_003906
KBio2_006474
KBio3_001319
KBioGR_000888
KBioSS_001338
Lopac0_000238
Lopac-C-0768
LS-1302
LS-99787
Lyophilized Cytoxan
Mitoxan
MolPort-001-783-420
Monohydrate, cyclophosphamide
N,N-Bis(2-chloroethyl)-1,3,2-oxazaphosphinan-2-amine 2-oxide
N,N-Bis(2-chloroethyl)tetrahydro-2H-1,3,2-oxazaphosphorin-2-amine 2-oxide
NCGC00015209-01
NCGC00015209-03
NCGC00015209-06
NCGC00091741-02
NCGC00091741-03
NCI60_002097
NCI-C04900
Neosar
NINDS_000246
NSC 26271
NSC26271
NSC-26271
NSC273033
NSC273034
Occupation, cyclophosphamide exposure
Procytox
RCRA waste no. U058
Rcra waste number U058
Rcra Waste Number U058
Revimmune
S1217_Selleck
Semdoxan
Sendoxan
Senduxan
SK 20501
SPBio_001071
Spectrum_000858
Spectrum2_001146
Spectrum3_000370
Spectrum4_000304
Spectrum5_000795
STK177249
STOCK2S-91217
UNII-6UXW23996M
WLN: T6MPOTJ BO BN2G2G
Zyklophosphamid
Zyklophosphamid [German]
|
|
19 |
|
Mecasermin |
Approved, Investigational |
Phase 1, Phase 2 |
|
68562-41-4 |
|
Synonyms:
Human somatomedin C
Mecasermin recombinant
|
Mecasermina
Mechano growth factor
|
|
20 |
|
Folic acid |
Approved, Nutraceutical, Vet_approved |
Phase 2 |
|
59-30-3 |
6037 |
Synonyms:
(2S)-2-[[4-[(2-amino-4-oxo-1H-pteridin-6-yl)methylamino]benzoyl]amino]pentanedioic acid
01769_FLUKA
2d0k
33609-88-0
36653-55-1 (mono-potassium salt)
59-30-3
6484-89-5 (mono-hydrochloride salt)
AC-11682
AC1L1LNX
Acfol (Spain)
Acide folique
Acide folique [INN-French]
Acido folico
ácido fólico
Acido folico [INN-Spanish]
Acidum folicum
Acidum folicum [INN-Latin]
Acifolic
AI3-26387
AKOS000503224
Antianemia factor
Apo-Folic
ARONIS014410
b9, Vitamin
BIDD:ER0563
BIDD:GT0641
BIF0608
bmse000299
BPBio1_000654
BSPBio_000594
BSPBio_002338
C00504
C20H20N6O6
CAS-59-30-3
CCRIS 666
CHEBI:27470
CHEMBL1622
CID6037
CPD000471860
Cytofol
D00070
DB00158
DivK1c_000494
Dosfolat b activ
Dosfolat B activ
EINECS 200-419-0
F0043
F7876_SIAL
F7876_SIGMA
F8758_SIGMA
F8798_SIAL
F8890_SIGMA
Facid
Factor U
FOL
Folacid
Folacin
Folaemin
Folaemin [Netherlands]
Folan
Folasic (Australia)
Folate
Folbal
Folcidin
Folcidin (VAN)
Folcysteine
Foldine
Foldine [France]
Folettes
Foliamin
Folic
folic acid
Folic acid
Folic acid (JP15/USP/INN)
Folic acid (TN)
Folic acid [BAN:INN:JAN]
Folic acid [INN:BAN:JAN]
Folic acid dihydrate
Folic acid, (D)-isomer
Folic acid, (DL)-isomer
Folic acid, calcium salt (1:1)
Folic acid, monopotassium salt
Folic acid, monosodium salt
Folic acid, potassium salt
Folic acid, sodium salt
Folicet
Folicet (TN)
Folico
Folico (Italy)
Folina
Folina (Italy)
|
Folipac
Folsaeure
Folsan
Folsaure
Folsäure
Folsav
Folvite
Folvron
Glutamic acid, N-(p-(((2-amino-4-hydroxypyrimido(4,5-b)pyrazin-6-yl)methyl)amino)benzoyl)-, L
HMS1921D20
HMS2092N17
HMS501I16
HSDB 2002
IDI1_000494
Incafolic
InChI=1/C19H19N7O6/c20-19-25-15-14(17(30)26-19)23-11(8-22-15)7-21-10-3-1-9(2-4-10)16(29)24-12(18(31)32)5-6-13(27)28/h1-4,8,12,21H,5-7H2,(H,24,29)(H,27,28)(H,31,32)(H3,20,22,25,26,30)/t12-/m0/s
KBio1_000494
KBio2_001861
KBio2_004429
KBio2_006997
KBio3_001558
KBioGR_002222
KBioSS_001861
Kyselina listova
Kyselina listova [Czech]
Liver lactobacillus casei factor
Liver Lactobacillus casei factor
LS-2157
Millafol
Mission prenatal
Mittafol
MLS001304016
MLS001335861
MolPort-004-285-551
N-(4-(((2-Amino-1,4-dihydro-4-oxo-6-pteridinyl)methyl)amino)benzo- yl)-L-glutamic acid
N-(4-((2-Amino-1,4-dihydro-4-oxo-6-pteridinyl)methyl)amino)benzoyl)-L-glutamic acid
N-(4-{[(2-amino-4-oxo-1,4-dihydropteridin-6-yl)methyl]amino}benzoyl)-L-glutamic acid
N-(4-{[(2-amino-4-oxo-3,4-dihydropteridin-6-yl)methyl]amino}benzoyl)-L-glutamic acid
N-(p-(((2-Amino-4-hydroxy-6-pteridinyl)methyl)amino)benzoyl)-L-glutamic acid
N-[(4-{[(2-amino-4-oxo-1,4-dihydropteridin-6-yl)methyl]amino}phenyl)carbonyl]-L-glutamate
N-[(4-{[(2-amino-4-oxo-1,4-dihydropteridin-6-yl)methyl]amino}phenyl)carbonyl]-L-glutamic acid
N-[4-[[(2-amino-3,4-dihydro-4-oxo-6-Pteridinyl)methyl]amino]benzoyl]-L-glutamic acid
NCGC00016265-01
NCGC00142391-01
nchembio.108-comp10
Nifolin
Nifolin [Denmark]
NINDS_000494
Novofolacid
Novofolacid [Canada]
N-Pteroyl-L-glutamate
N-pteroyl-L-glutamic acid
N-Pteroyl-L-glutamic acid
NSC 3073
PGA
PGA (VAN)
Prestwick_230
Prestwick3_000627
PteGlu
Pteroylglutamate
Pteroylglutamic acid
Pteroyl-L-glutamate
Pteroyl-L-glutamic acid
Pteroyl-L-monoglutamate
Pteroyl-L-monoglutamic acid
Pteroylmonoglutamate
Pteroylmonoglutamic acid
SAM002264616
SDCCGMLS-0066738.P001
Serum Folate Level
SMP2_000137
SMR000471860
SPBio_001357
Spectrum_001381
SPECTRUM1502020
Spectrum2_001459
Spectrum3_000749
Spectrum4_001751
Spectrum5_000602
UNII-935E97BOY8
Usaf cb-13
Vitamin B11
Vitamin b9
Vitamin B9
Vitamin Bc
Vitamin BC
Vitamin be
Vitamin Be
Vitamin m
Vitamin M
|
|
21 |
|
Phenylalanine |
Approved, Investigational, Nutraceutical |
Phase 2 |
|
63-91-2 |
6140 |
Synonyms:
(-)-beta-Phenylalanine
(2S)-2-amino-3-phenylpropanoic acid
(L)-Phenylalanine
(S)-(-)-Phenylalanine
(S)-2-amino-3-Phenylpropanoate
(S)-2-amino-3-Phenylpropanoic acid
(S)-2-Amino-3-phenylpropanoic acid
(S)-2-amino-3-Phenylpropionate
(S)-2-amino-3-Phenylpropionic acid
(S)-2-Amino-3-phenylpropionic acid
(S)-a-amino-b-Phenylpropionate
(S)-a-amino-b-Phenylpropionic acid
(S)-alpha-amino-Benzenepropanoate
(S)-alpha-Aminobenzenepropanoate
(S)-alpha-amino-Benzenepropanoic acid
(S)-alpha-Aminobenzenepropanoic acid
(S)-alpha-Amino-benzenepropanoic acid
(S)-alpha-amino-beta-Phenylpropionate
(S)-alpha-amino-beta-Phenylpropionic acid
(S)-alpha-Amino-beta-phenylpropionic acid
(S)-alpha-Aminohydrocinnamate
(S)-alpha-Aminohydrocinnamic acid
(S)-Phenylalanine
(S)-α-amino-β-phenylpropionate
(S)-α-amino-β-phenylpropionic acid
10549-09-4
1f2p
1F9436B3-8B0D-4AC6-A004-4249B0BDA436
1usi
3-[4-[bis(2-chloroethyl)amino]phenyl]-2-formamidopropanoic acid
303-47-9 OCHRATOXINA
32526-17-3
35849-41-3
3617-44-5
3-Phenylalanine
3-phenyl-l-alanine
3-phenyl-L-alanine
3-Phenyl-L-alanine
5297-02-9
63-91-2
673-06-3 D-PHENYL)
67675-33-6
78019_FLUKA
78019_SIGMA
801204-11-5
AB1003608
AC1L1LVU
AC1L1XF0
alpha-Aminohydrocinnamate
alpha-Aminohydrocinnamic acid
AmbotzHAA1121
Antibiotic FN 1636
beta-Phenylalanine
beta-Phenyl-alpha-alanine
beta-phenyl-l-alanine
beta-Phenyl-L-alanine
bmse000045
b-Phenyl-L-alanine
C00079
CB 3208
CCRIS 4254
CHEBI:17295
CHEMBL301523
CID37278
CID6140
D00021
DB00120
|
DB02556
EINECS 200-568-1
endophenyl
Endorphenyl
F
FEMA No. 3585
fenilalanina
Fenilalanina
Fenilalanina [Spanish]
H-Phe-OH
HSDB 1825
L-2-amino-3-Phenylpropionate
L-2-amino-3-Phenylpropionic acid
L-3-(p-(Bis(2-chloroethyl)amino)phenyl)-N-formylalanine
L-Antibiotic FN 1636
L-Isomer phenylalanine
L-PHENYL ALANINE (SEE ALSO 22839-47-0, ASPARTAME
L-phenylalanine
L-Phenylalanine
L-Phenylalanine (JP15)
L-Phenylalanine,
L-Phenylalanine, 4-(bis(2-chloroethyl)amino)-N-formyl- (9CI)
L-PHENYLALININE
LS-1515
LS-15879
MolPort-001-757-101
NCGC00013103
NCGC00095047-01
NCGC00095047-02
NCGC00095047-03
NCGC00095047-04
nchembio.185-comp8
nchembio.186-comp89
nchembio.255-comp2
nchembio816-comp8
NCI9959
NCIStruc1_000204
NCIStruc2_000248
N-Formyl-L-p-sarcolysin
N-Formyl-L-sarcolysin
N-Formylmelphalan
NSC 37024
NSC 79477
NSC37024
NSC-9959
P0134
P2126_SIAL
P5482_SIGMA
P8740_SIAL
P8740_SIGMA
phe
Phe
Phenylalamine
phenylalanine
Phenylalanine
Phenyl-alanine
PHENYLALANINE
Phenylalanine (USP/INN)
Phenylalanine (VAN)
Phenylalanine [USAN:INN:JAN]
Phenylalanine, L isomer
Phenylalanine, L-isomer
Phenylalaninum
Phenylalaninum [Latin]
UNII-47E5O17Y3R
W358509_ALDRICH
β-phenyl-L-alanine
|
|
22 |
|
Vitamin B Complex |
|
Phase 2 |
|
|
|
23 |
|
Folic Acid Antagonists |
|
Phase 2 |
|
|
|
24 |
|
Folate |
|
Phase 2 |
|
|
|
25 |
|
Vitamin B9 |
|
Phase 2 |
|
|
|
26 |
|
Micronutrients |
|
Phase 2 |
|
|
|
27 |
|
Antidotes |
|
Phase 2 |
|
|
|
28 |
|
Vitamins |
|
Phase 2 |
|
|
|
29 |
|
Hematinics |
|
Phase 2 |
|
|
|
30 |
|
Nutrients |
|
Phase 2 |
|
|
|
31 |
|
Trace Elements |
|
Phase 2 |
|
|
|
32 |
|
Antimetabolites |
|
Phase 2 |
|
|
|
33 |
|
Lipid Regulating Agents |
|
Phase 2 |
|
|
|
34 |
|
Hypolipidemic Agents |
|
Phase 2 |
|
|
|
35 |
|
Anticholesteremic Agents |
|
Phase 2 |
|
|
|
36 |
|
Antineoplastic Agents, Immunological |
|
Phase 2 |
|
|
|
37 |
|
Anti-HIV Agents |
|
Phase 2 |
|
|
|
38 |
|
Adjuvants, Immunologic |
|
Phase 2 |
|
|
|
39 |
|
Plerixafor octahydrochloride |
|
Phase 2 |
|
|
|
40 |
|
Antiviral Agents |
|
Phase 2 |
|
|
|
41 |
|
Anti-Retroviral Agents |
|
Phase 2 |
|
|
|
42 |
|
Thymoglobulin |
|
Phase 2 |
|
|
|
43 |
|
Antilymphocyte Serum |
|
Phase 2 |
|
|
|
44 |
|
Antibodies, Monoclonal |
|
Phase 1, Phase 2 |
|
|
|
45 |
|
Insulin, Globin Zinc |
|
Phase 1, Phase 2 |
|
|
|
46 |
|
Hormones |
|
Phase 1, Phase 2 |
|
|
|
47 |
|
Mitogens |
|
Phase 1, Phase 2 |
|
|
|
48 |
|
insulin |
|
Phase 1, Phase 2 |
|
|
|
49 |
|
Zidovudine |
Approved |
Phase 1 |
|
30516-87-1 |
35370 |
Synonyms:
1-(3-Azido-2,3-dideoxy-beta-D-ribofuranosyl)thymine
3' azido 2',3' Dideoxythymidine
3' Azido 2',3' Dideoxythymidine
3' azido 3' Deoxythymidine
3' Azido 3' deoxythymidine
3&prime
30516-87-1
399024-19-2
3'-azido-2',3'-Dideoxythymidine
3'-Azido-2',3'-Dideoxythymidine
3'-azido-3'-Deoxythymidine
3'-Azido-3'-deoxythymidine
3-Azido-3-deoxythymidine
3'-Azido-3'-deoxythymidine & Concanavalin A
3'-Azido-3'-deoxythymidine & Erythropoietin
3'-Azido-3'-deoxythymidine & Heteropolyoxotungstate PM-19
3'-Azido-3'deoxythymidine & Interferon .alpha.
3'-Azido-3'-deoxythymidine & Interleukin-1
3'-Azido-3'-deoxythymidine & Interleukin-2
3'-Azido-3'-deoxythymidine & Interleukin-6
3'-Azido-3'-deoxythymidine & Lithium & Erythropoietin
3'-Azido-3'-deoxythymidine & Lithium & Interleukin-1
3'-Azido-3'-deoxythymidine & Lithium & Interleukin-6
3'-Azido-3'-deoxythymidine & Lymphoblastoid Interferon
3'-Azido-3'-deoxythymidine & Sho-Saiko-To
3'-Azido-3'-deoxythymidine (AIDS)
3'-azido-3'-deoxythymidine, AZT
3'-Azidothymidine
3'-Deoxy-3'-azidothymidine
A2169_SIGMA
AC1L1TKL
AC1Q2OEK
antiviral
Antiviral azt
Antiviral AZT
Apo-Zidovudine
-Azido-3&prime
azidodeoxythymidine
Azidothymidine
AZT
AZT & CD4(178)-PE 40
AZT & Colony-stimulating factor 2
AZT & Concanavalin A (ConA)
AZT & EPO
AZT & GM-CSF
AZT & HPA
AZT & IFN.alpha.
AZT & IL-1
AZT & IL-2
AZT & IL-6
AZT & Interferon-.alpha.-2
AZT & Li & EPO
AZT & Li & GM-CSF
AZT & Li & IL-1
AZT & Li & IL-6
AZT & Lymphoblastoid Interferon
AZT & NP (from PHCA or HSA)
AZT & PM-19
AZT & rIFN.alpha.2
AZT & rsCD4 & rIFN.alpha.A
AZT & rsT4
AZT & sCD4
AZT & srCD4
AZT & SST
AZT (antiviral)
AZT (Antiviral)
AZT antiviral
AZT Antiviral
AZT TRANSPLACENTAL CARCINOGENESIS STUDY
AZT, antiviral
AZT, Antiviral
AZT+PRO 140
Aztec
BB_NC-1012
BPBio1_000403
BRD-K72903603-001-04-6
BSPBio_000365
BSPBio_003153
BW a509U
BW A509U
BWA 509u
BWA 509U
BW-A 509U
BWA509u
BWA-509u
BWA509U
BWA-509U
BW-A509U
BW-A-509U
C07210
|
CCRIS 105
CHEBI:10110
CHEBI:127307
CHEMBL129
CID35370
Compound S
Cpd S
CPD000058351
D00413
D015215
DB00495
-deoxythymidine
DivK1c_000524
DRG-0004
DS-4152 & AZT
HMS1921J20
HMS2090G11
HMS2092D06
HMS501K06
HSDB 6515
IDI1_000524
Interferon AD + 3'-azido-3'-deoxythymidine
Intron A & AZT
K7 [P Ti2 W10 O40]
KBio1_000524
KBio2_001828
KBio2_004396
KBio2_006964
KBio3_002653
KBioGR_000703
KBioSS_001828
Liposomal AZT-SN-1
Liposomal AZT-SN-3
LS-1159
Met-SDF-1.beta. & AZT
Met-SDF-1.beta. & Zidovudine
MLS000028548
MLS001055351
MLS001076358
MLS002153202
MLS002222249
MolPort-002-507-286
NCGC00023945-03
NCGC00023945-04
NCGC00023945-05
NCGC00023945-08
NCGC00178237-01
NCGC00178237-02
NINDS_000524
Novo-Azt
NSC 602670
PC-SOD+AZT
Prestwick3_000333
Propolis+AZT
Racemic Liposomal AZT
racemic-dipalmitoylglycerophospho-AZT (in a lipid vesicle)
Retrovir
Retrovir (TN)
Retrovir(TM)
rIFN-beta seron & AZT
SAM002548971
SMR000058351
SN-1-dipalmitoylglycerophospho-AZT (in a lipid vesicle)
SN-3-dipalmitoylglycerophospho-AZT (in a lipid vesicle)
SPBio_000834
Spectrum_001348
SPECTRUM1502109
Spectrum2_000927
Spectrum3_001507
Spectrum4_000332
Spectrum5_001101
STK801891
UNII-4B9XT59T7S
ZDV
zidovudin
Zidovudin
Zidovudina
Zidovudina [Spanish]
zidovudine
Zidovudine
Zidovudine (JAN/USP/INN)
ZIDOVUDINE [AZT]
Zidovudine [USAN:INN:BAN:JAN]
Zidovudine EP III
Zidovudine+PRO 140
Zidovudinum
Zidovudinum [Latin]
ZINC03779042
ZVD
|
|
50 |
|
Aldesleukin |
Approved |
Phase 1 |
|
85898-30-2, 110942-02-4 |
|
Synonyms:
125-L-serine-2-133-interleukin 2 (human reduced)
Aldesleukina
Interleukin-2 aldesleukin
|
Interleukin-2(2-133),125-ser
Recombinant interleukin-2 human
|
|
Interventional clinical trials:
(show top 50)
(show all 85)
# |
Name |
Status |
NCT ID |
Phase |
Drugs |
1 |
Methodology Study to Investigate the Utility of Retroviral Insertion Site Analysis in Samples From Subjects Treated With Strimvelisâ„¢ Gene Therapy |
Not yet recruiting |
NCT03311074 |
Phase 4 |
|
2 |
Risk-Adapted Allogeneic Stem Cell Transplantation For Mixed Donor Chimerism In Patients With Selected Non-Malignant Diseases |
Unknown status |
NCT01019876 |
Phase 2, Phase 3 |
Fludarabine;Cyclophosphamide;Cyclophosphamide 40;Cyclophosphamide 30 |
3 |
A Study of EZN-2279 (Polyethylene Glycol Recombinant Adenosine Deaminase [PEG-rADA]) Administered as a Weekly Intramuscular Injection in Patients With Adenosine Deaminase (ADA)-Deficient Combined Immunodeficiency |
Completed |
NCT01420627 |
Phase 3 |
|
4 |
IGIV-C 10% Rapid Infusion Trial in Primary Immune Deficient Patients |
Completed |
NCT00220766 |
Phase 3 |
Immune Globulin Intravenous [Human], 10% Caprylate/Chromatography Purified;Dextrose, 5% in Water |
5 |
A Single Arm, Open Label Clinical Study to Enable Process Validation of Commercial Grade Ex Vivo Hematopoietic Stem Cell Gene Therapy (OTL-101) in Subjects With Severe Combined Immunodeficiency Due to Adenosine Deaminase Deficiency (ADA-SCID) |
Recruiting |
NCT04140539 |
Phase 2, Phase 3 |
|
6 |
Protocol No. 2 of Gene Therapy for X-linked Severe Combined Immunodeficiency (SCID-X1) Using a Self Retroviral Vector - SCID2 |
Unknown status |
NCT01410019 |
Phase 1, Phase 2 |
|
7 |
Phase I Gene Therapy Protocol for Adenosine Deaminase Deficiency |
Completed |
NCT01279720 |
Phase 1, Phase 2 |
|
8 |
Treatment of ADA-SCID by Gene Therapy on Somatic Cells |
Completed |
NCT00599781 |
Phase 1, Phase 2 |
|
9 |
Efficacy and Safety of Cryopreserved Formulation of Autologous CD34+ Hematopoietic Stem Cells Transduced Ex Vivo With EFS Lentiviral Vector Encoding for Human ADA Gene in Subjects With Severe Combined Immunodeficiency Due to ADA Deficiency |
Completed |
NCT02999984 |
Phase 1, Phase 2 |
busulfan;PEG-ADA ERT |
10 |
Phase I/II, Historical Controlled, Open-label, Non-randomised, Single-centre Trial to Assess the Safety and Efficacy of EF1αS-ADA Lentiviral Vector Mediated Gene Modification of Autologous CD34+ Cells From ADA-deficient Individuals |
Completed |
NCT01380990 |
Phase 1, Phase 2 |
Busulfan;Peg-Ada |
11 |
Phase I/II Trial of De-Escalation of Busulfan With Fludarabine and Antithymocyte Globulin as Preparative Therapy for Hematopoietic Stem Cell Transplant for the Treatment of Severe Congenital T-Cell Immunodeficiency |
Completed |
NCT00228852 |
Phase 1, Phase 2 |
Busulfan, Fludarabine and ATG |
12 |
Autologous Transplantation of Bone Marrow CD34+ Stem/Progenitor Cells After Addition of a Normal Human ADA cDNA by the EFS-ADA Lentiviral Vector for Severe Combined Immunodeficiency Due to Adenosine Deaminase Deficiency (ADA-SCID) |
Completed |
NCT01852071 |
Phase 1, Phase 2 |
busulfan;PEG-ADA ERT |
13 |
ADA Gene Transfer Into Hematopoietic Stem/Progenitor Cells for the Treatment of ADA-SCID |
Completed |
NCT00598481 |
Phase 2 |
|
14 |
MND-ADA Transduction of CD34+ Cells From the Bone Marrow Of Children With Adenosine Deaminase (ADA)-Deficient Severe Combined Immunodeficiency (SCID): Effect of Discontinuation of PEG-ADA and Marrow Cytoreduction With Busulfan |
Completed |
NCT00794508 |
Phase 2 |
|
15 |
Mechanisms of Antifolate Efficacy in Arthritis |
Completed |
NCT00000395 |
Phase 2 |
Methotrexate |
16 |
A Phase II Trial of Reduced Intensity Allogeneic Stem Cell Transplantation With Fludarabine, Melphalan and Low Dose Total Body Irradiation |
Completed |
NCT01529827 |
Phase 2 |
fludarabine phosphate;melphalan;tacrolimus;mycophenolate mofetil;methotrexate |
17 |
Cord Blood Stem Cell Transplantation Study (COBLT) |
Completed |
NCT00000603 |
Phase 2 |
|
18 |
A Phase II Study of Reduced Intensity Conditioning in Pediatric Patients and Young Adults ≤55 Years of Age With Non-Malignant Disorders Undergoing Umbilical Cord Blood, Bone Marrow, or Peripheral Blood Stem Cell Transplantation |
Recruiting |
NCT01962415 |
Phase 2 |
Hydroxyurea;Alemtuzumab;Fludarabine;Melphalan;Thiotepa |
19 |
Gene Transfer for X-linked Severe Combined Immunodeficiency (SCID-X1) Using a Self-inactivating Lentiviral Vector (TYF-IL-2Rg) |
Recruiting |
NCT03217617 |
Phase 1, Phase 2 |
|
20 |
Efficacy and Safety of a Cryopreserved Formulation of Autologous CD34+ Haematopoietic Stem Cells Transduced ex Vivo With Elongation Factor 1α Short Form (EFS) Lentiviral Vector Encoding for Human ADA Gene in Subjects With Severe Combined Immunodeficiency (SCID) Due to Adenosine Deaminase Deficiency |
Recruiting |
NCT03765632 |
Phase 1, Phase 2 |
Busulfan;Peg-Ada |
21 |
Lentiviral Gene Transfer for Treatment of Children Older Than 2 Years of Age With X-Linked Severe Combined Immunodeficiency |
Recruiting |
NCT03315078 |
Phase 1, Phase 2 |
Palifermin;Busulfan |
22 |
A Phase I/II Study Evaluating the Safety and the Efficacy of Human T Lymphoid Progenitor (HTLP) Injection to Accelerate Immune Reconstitution After Partially HLA Compatible Allogeneic Hematopoietic Stem Cell Transplantation in SCID Patients |
Recruiting |
NCT03879876 |
Phase 1, Phase 2 |
|
23 |
Haplocompatible Transplant Using TCRα/β Depletion Followed by CD45RA-Depleted Donor Lymphocyte Infusions for Severe Combined Immunodeficiency (SCID) |
Recruiting |
NCT03597594 |
Phase 1, Phase 2 |
Anti-thymocyte globulin (rabbit);Busulfan;Fludarabine;Thiotepa |
24 |
Phase I/II Trial of Lentiviral Gene Transfer for SCID-X1 With Low Dose Targeted Busulfan Conditioning |
Recruiting |
NCT03311503 |
Phase 1, Phase 2 |
|
25 |
A Study of Hematopoietic Stem Cell Transplantation (HSCT) in Immune Function Disorders Using a Reduced Intensity Preparatory Regime |
Recruiting |
NCT01821781 |
Phase 2 |
Transplant preparative regimen of alemtuzumab, fludarabine, thiotepa, and melphalan |
26 |
A Phase I/II Feasibility Study of Gene Transfer for Artemis-Deficient Severe Combined Immunodeficiency (ART-SCID) Using a Self-Inactivating Lentiviral Vector (AProArt) to Transduce Autologous CD34 Hematopoietic Cells |
Recruiting |
NCT03538899 |
Phase 1, Phase 2 |
AProArt;Busulfan |
27 |
PEDS024, Phase I/II Feasibility Study of Busulfan Fludarabine and Thiotepa Conditioning Regimen for Allogeneic Hematopoietic Stem-Cell Transplantation (HSCT) for Children With Non-Malignant Disorders |
Recruiting |
NCT03513328 |
Phase 1, Phase 2 |
Thiotepa--single daily dose;Thiotepa--escalated dose |
28 |
Phase II Study for Patients With Primary Immunodeficiencies Using and Cd19+ Depleted Unrelated Donor or Partially Matched Related Donor Peripheral Stem Cells |
Recruiting |
NCT02990819 |
Phase 2 |
|
29 |
A Pilot Feasibility Study of Gene Transfer for X-Linked Severe Combined Immunodeficiency in Newly Diagnosed Infants Using a Self-Inactivating Lentiviral Vector to Transduce Autologous CD34+ Hematopoietic Cells |
Recruiting |
NCT01512888 |
Phase 1, Phase 2 |
Busulfan |
30 |
Lentiviral Gene Transfer for Treatment of Children Older Than 2 Years of Age With X-Linked Severe Combined Immunodeficiency |
Recruiting |
NCT01306019 |
Phase 1, Phase 2 |
Palifermin;Busulfan |
31 |
Ezetimibe as a Safe and Efficacious Treatment for Chronic Hepatitis C |
Recruiting |
NCT02971033 |
Phase 2 |
20mg ezetimibe;Placebo;40mg ezetimibe |
32 |
A Randomized Trial of Low Versus Moderate Exposure Busulfan for Infants With Severe Combined Immunodeficiency (SCID) Receiving TCRαβ+/CD19+ Depleted Transplantation: A Phase II Study by the Primary Immune Deficiency Treatment Consortium (PIDTC) and Pediatric Blood and Marrow Transplant Consortium (PBMTC) |
Recruiting |
NCT03619551 |
Phase 2 |
Busulfan |
33 |
Multi-institutional Phase I/II Trial Evaluating the Treatment of SCID-X1 Patients With Retrovirus-mediated Gene Transfer |
Active, not recruiting |
NCT01129544 |
Phase 1, Phase 2 |
|
34 |
Bilateral Orthotopic Lung Transplant in Tandem With CD3+ and CD19+ Cell Depleted Bone Marrow Transplant From Partially HLA-Matched Cadaveric Donors |
Enrolling by invitation |
NCT01852370 |
Phase 1, Phase 2 |
|
35 |
Matched Related and Unrelated Donor Stem Cell Transplantation for Severe Combined Immune Deficiency (SCID): Busulfan-based Conditioning With h-ATG, Radiation, and Sirolimus |
Enrolling by invitation |
NCT04370795 |
Phase 1, Phase 2 |
Sirolimus;Busulfan;Horse -Anti-thymocyte;G-CSF |
36 |
Hematopoietic Stem Cell Transplantation for Children With Severe Combined Immunodeficiency Disease Utilizing Alemtuzumab and Mobilization With Plerixafor & Filgrastim |
Terminated |
NCT01182675 |
Phase 2 |
Transplant Conditioning with Mobilization Only;Transplant Conditioning with Mobilization and Alemtuzumab |
37 |
CD45 and Alemtuzumab Monoclonal Antibody Conditioning Regimen For Allogeneic Donor Stem Cell Transplantation Of Patients With Severe Combined Immunodeficiency Disease (SCID) And Other Primary Immunodeficiency Disorders |
Terminated |
NCT00579137 |
Phase 1, Phase 2 |
Fludarabine |
38 |
Treatment for Growth Failure in Patients With X-Linked Severe Combined Immunodeficiency (XSCID): A Phase 2 Study Assessing Safety and Clinical Response to Treatment With Insulin-like Growth Factor-1 (IGF-1) |
Terminated |
NCT00490100 |
Phase 1, Phase 2 |
Increlex |
39 |
Phase I/II Trial of Hematopoietic Stem Cell Transplant (HSCT) for Children With Severe Combined Immune Deficiency (SCID) and Without an HLA-Matched Sibling Donor |
Terminated |
NCT02127892 |
Phase 1, Phase 2 |
|
40 |
Allogeneic Hematopoietic Cell Transplantation for Patients With Acute Lymphoblastic Leukemia in Remission Using HLA-matched Sibling Donors, HLA-matched Unrelated Donors, or HLA-mismatched Familial Donors-A Phase 2 Study |
Terminated |
NCT01037764 |
Phase 2 |
|
41 |
Sirolimus in Prevention of aGVHD in Maternally Engrafted (TME) Severe Combined Immunodeficiency (SCID) Infants Receiving Unconditioned Hematopoietic Stem Cell Transplant (HSCT) |
Withdrawn |
NCT02177760 |
Phase 2 |
Sirolimus |
42 |
Transplantation of Highly Purified Haploidentical CD133 Hematopoietic Cells in Children With Severe Combined Immunodeficiency Syndrome |
Completed |
NCT00152100 |
Phase 1 |
Filgrastim, Alemtuzumab |
43 |
Induction of Mixed Hematopoietic Chimerism in Patients With Severe Combined Immunodeficiency Disorders Using Allogeneic Bone Marrow and Post-Transplant Immunosuppression With Cyclosporine and Mycophenolate Mofetil |
Completed |
NCT00008450 |
Phase 1 |
Cyclosporine;Mycophenolate Mofetil |
44 |
Treatment of SCID Due to ADA Deficiency With Autologous Cord Blood or Bone Marrow CD34+ Cells Transduced With a Human ADA Gene |
Completed |
NCT00018018 |
Phase 1 |
CD34+ cells transduced with ADA retrovir |
45 |
Ex Vivo Retroviral Gene Transfer For Treatment of X-Linked Severe Combined Immunodeficiency (XSCID) |
Completed |
NCT00028236 |
Phase 1 |
Gene-Transduced Autologous CD34+ Stem Cells |
46 |
Treatment of SCID Due to ADA Deficiency With Autologous Transplantation of Cord Blood or Hematopoietic CD 34+ Cells After Addition of a Normal Human ADA cDNA by the EFS-ADA Lentiviral Vector |
Completed |
NCT02022696 |
Phase 1 |
|
47 |
Phase I/II Trial of Recombinant Interleukin-2 In Symptomatic Human Immunodeficiency Virus-Infected Children |
Completed |
NCT00000849 |
Phase 1 |
Aldesleukin |
48 |
Treatment of EBV, CMV, and Adenovirus Infections in Primary Immunodeficiency Disorders With Viral-specific Cytotoxic T-Lymphocytes |
Completed |
NCT02510404 |
Phase 1 |
|
49 |
Phase I/II Study of Lentiviral Gene Transfer for SCID-X1 With Low Dose Targeted Busulfan |
Recruiting |
NCT03601286 |
Phase 1 |
Lentiviral vector transduced CD34+ cells |
50 |
A Phase 1 Study to Evaluate the Safety and Tolerability of Tandemly-purified Allogenic CD34+CD90+ HSC Administered Following Conditioning With AMG 191 to Achieve Engraftment and Immune Reconstitution in Patients With SCID |
Recruiting |
NCT02963064 |
Phase 1 |
|
Inferred drug relations via
UMLS
71
/
NDF-RT
50
:
|